TIL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	9 828.00
Average Volume	20 055.00
Market Cap	69.20M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-2.16 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.440
ATR14	$0.0450 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-10	Laumas Sandeep	Buy	80 000	Employee Stock Option (right to buy)
2024-02-10	Crouch Bronson	Buy	120 000	Employee Stock Option (right to buy)
2023-06-14	Binder Gwendolyn	Buy	1 500	Stock Option (Right to Buy)
2023-06-14	Mcgaughy R Kent Jr	Buy	1 500	Stock Option (Right to Buy)
2023-06-14	Gibson Neil W	Buy	1 500	Stock Option (Right to Buy)

INSIDER POWER
96.69
Last 92 transactions
Buy: 125 955 560 \| Sell: 140 779 900

Till Capital Ltd. Correlation

10 Most Positive Correlations
SLNH	0.963
AVCT	0.951
TFFP	0.945
MRACW	0.941
NRBO	0.936
ULBI	0.93
WISA	0.93
ONCS	0.927
RMRM	0.923
TOI	0.923

10 Most Negative Correlations
VLYPO	-0.949
IART	-0.933
MDLZ	-0.926
PPH	-0.92
SLGN	-0.918
MNST	-0.918
NRIM	-0.912
KLAC	-0.91
RFEU	-0.907
ROST	-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Till Capital Ltd. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-4.76M (0.00 %)
EPS:	$-24.00

Q4	2023
Revenue:	$0
Gross Profit:	$-1.04M (0.00 %)
EPS:	$-1.990

Q3	2023
Revenue:	$0
Gross Profit:	$-953 000 (0.00 %)
EPS:	$-10.37

Q2	2023
Revenue:	$0
Gross Profit:	$-835 000 (0.00 %)
EPS:	$-2.87

Financial Reports:

No articles found.

Till Capital Ltd.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.